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Introduction: Diffused large B-cell lymphomas (DLBCL) is the most common aggressive non-
Hodgkin lymphoma (NHL) worldwide, constituting up to 40% of all cases globally. The 
incidence of HIV-associated lymphoma has decreased since the introduction of combination 
antiretroviral therapy (cART) in the mid-1990s. However, NHL, especially DLBCL remains 
the most common cause of morbidity and mortality among people living with HIV/AIDS, 
especially in sub-Saharan Africa where 70% of the global HIV/AIDS population reside. Gene 
expression profiles (GEP) identified based on the cell of origin (COO) two distinct DLBCL 
subtypes; germinal-centre B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL. These 
subtypes differ in their genetic abnormalities and response to treatment regimens. 
Aim: We aimed to investigate in detail, protein distribution profile from FFPE tissue in HIV 
and non-HIV related DLBCL subtypes. 
Methods: FFPE DLBCL lymph node tissue samples from HIV and non-HIV related DLBCL 
were subjected to MALDI-imaging, in order to get the spatial distribution of proteins in DLBCL 
tissue. Proteins were extracted from tissue samples and subjected to liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS) to identify proteins present in FFPE 
DLBCL tissue. The protein profiles from the above-mentioned samples were compared and 
characterized by cancer pathways.   
Results: This study had 12 DLBCL cases and 2 human tonsil controls diagnosed from 2009-
2011. These cases were retrieved using the NHLS database. The overall age of DLBCL patients 
by the time they were diagnosed ranged from 18 to 73 years, with a median age of 48 years. 
MALDI-IMS peak detection function identified 1466 different m/z values from both the HIV 
negative and HIV positive DLBCL cases. There were only 50 exclusive m/z values that 
distinguished the DLBCL subtypes, Using LC-MS/MS we identified a total of 88 proteins, by 
comparing these proteins, we observed 6 differentially expressed among the DLBCL subtypes 
and controls Fructose-bisphosphate aldolase C was the only significantly differentially 
expressed proteins between HIV negative ABC DLBCL and HIV positive ABC DLBCL 
subtype (p value=1,47738).  
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Conclusion: Using proteomic techniques, we identified and visualized differentially expressed 
protein in DLBCL subtypes and controls. The majority of these proteins belonged to glycolysis, 






















1. Introduction  
The war against cancer is approaching its 50th anniversary, and yet cancer remains the second 
leading cause of death globally. According to the World Health Organization (WHO), cancer 
was liable for an estimated 9,6 million deaths in 2018 1. Recent discoveries from the Human 
Genome Project have improved our understanding of the disease, with the use of 
immunotherapy acknowledged as the fourth pillar of cancer treatment, along with radiation, 
surgery and chemotherapy 2. 
Cancer is a complex disease, characterised by the proliferation of abnormal cells (known as the 
tumour). These cells undergo mutations caused by different cancer-causing agents, such as; 
environmental agents, viral or genetic factors 3. For example, tobacco is associated with lung, 
bladder, mouth and throat cancers 4.  
Uncontrollable cell growth is the hallmark of cancer5. This is mainly due to the activation of 
oncogenes, which allows the proliferation and metastasis of abnormal cells5,6 (figure.1). 
 
 
Figure 1: Oncogene activation, shows how cancer genes (oncogenes) become activated by 




Cancer is usually diagnosed at “advance stages” (usually stages 3 and 4), and treatment is only 
effective in a few patients. Therefore, the discovery of clinically significant biomarkers can be 
used for diagnosis, prognosis and potential drug targets 7. The purpose of this study is to use 
modern proteomics technology to compare the differences in protein expression profiles of 























1.1 Diffuse Large B-cell Lymphoma 
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma 
(NHL) and is diagnosed in approximately 150,000 people annually8. According to the American 
Cancer Society, in 2017 there were 80 500 newly diagnosed lymphoma cases and 72 240 of 
those cases were NHL in the USA, thus ranking NHL among the top causes of death in the 
USA9. DLBCL is prevalent in young HIV positive patients and elderly patients, with the median 
age range of 60 to 80 years 10. 
DLBCL is characterised by the diffuse growth patterns of large and mature B-lymphocytes11. 
These cells are usually twice the size of normal lymphocytes12. The disease develops in the B-
lymphocytes, which are responsible for the production of immunoglobulin (Ig) in the lymphatic 
system12. Clinically, patients with DLBCL present with lymphadenopathy, caused by rapidly 
growing cancer cells in the lymph nodes. B symptoms such as weight loss, fever, and night 
sweats are associated with DLBCL, however, some patients present with symptoms that involve 
the organs  13–15.  
The aetiology of DLBCL in most cases is unknown. However, the pathogenesis of the disease 
involves the interplay between biological (sporadic or inherited mutations)  and environmental 
(carcinogens and pathogens) factors 16. Biological and environmental factors can act 
individually or in sequence to cause genetic mutations 6. Epstein-Barr virus (EBV)  is an 
example of a cancer-causing virus known to be associated with DLBCL17. The presence of EBV 
during the development of cancer is to induce cell proliferation and lymphangiogenesis through 
the activation of the NF-κB pathway 18,19. A study by Herndier and colleagues observed that 
the presence of both HIV and  EBV result in B-cell immortalisation, activation of EBV, and 
dysregulation of MYC20. EBV infection is common in the ABC DLBCL subtypes, and has an 
impact on the overall survival of patients21,22.  
The use of combination antiretroviral therapy (cART) in the mid-1990s has reduced the 
incidence of HIV-associated lymphomas in young patients 16,23.  However, NHL, especially 
DLBCL remains the most common cause of morbidity and mortality among people living with 
HIV/AIDS, especially in sub-Saharan Africa where 70% of the global HIV/AIDS population 
resides 24.  Little is known about how HIV induces lymphoma in HIV-associated lymphoma. 
Multiple factors that may induce lymphoma include oncogenic viruses, immune suppression, 
expression of cytokines that result in the proliferation of B-cells, or opportunistic infections 
such as EBV and herpesvirus22,2512,26,27.  Various studies suggest that low CD4 count increases 
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the presence of oncogenic viruses thus inducing abnormal cell growth 26,27. HIV-associated 
DLBCL has a high expression of immunoglobulin genes (Ig) and this results in the expansion 
of polyclonal and monoclonal B-cells 28. A study by Landgren found a high expression of serum 
immunoglobulin light chain in HIV-associated lymphomas 29. Thus, suggesting the use of 
serum immunoglobulin light chain as a prognostic marker for HIV-associated DLBCL29.  
 
1.2 Classification  
The WHO classification system in 2008 grouped DLBCL cases based on clinical and 
pathological features, into EBV positive DLBCL of the elderly, primary DLBCL of the central 
nervous system, T‐cell/histiocyte‐rich large cell lymphoma, and primary cutaneous DLBCL, 
leg type. However, the 2016 WHO classification system was revised and the DLBCL cases 
were classified based on the cell of origin, MYC, and BCL3 expression, as well as the EBV 
status30.  
1.2.1 Cell of origin (COO) 
On the bases of gene expression profiling (GEP), DLBCL is classified based on the COO into 
the germinal centre (GCB DLBCL) and activated B-cell (ABC DLBCL) subtype (figure 2) 31.  
The COO reflects the stage at which the disease developes  or the biological pathways involved 
in the development of the disease. The GCB subtype expresses the germinal centre associated 
genes, such as CD10, LM02, and BCL6 32–34. The genetic alterations associated with GCB 
DLBCL cases include c-rel (critical regulator) amplification, chromosomal translocation t (14; 
18), and histone methyltransferase EZH2 mutations 24–26. Somatic histone mutations within the 
EZH2 genes can work together with BCL6 genes to initiate the growth and development of 
GCB-DLBCL39,40. Various studies suggest the use of both EZH2 and BCL6 genes as selective 
drug targets for GCB DLBCL40–42. The cellular energy metabolism and growth of DLBCL are 
regulated by the activation of phosphatidylinositol 3 kinases due to PTEN gene mutation in 
both GCB DLBCL and ABC DLBCL 38,39. The expression mechanism of BCL2 differs in both 
the GCB DLBCL and ABC DLBCL. In the GCB subtype, BCL2 expression occurs through 
chromosomal translocation t (14; 18), while it occurs through gene amplification and 
transcriptional modification in the ABC subtype 39.  
The ABC DLBCL subtype expresses plasmablastic cells like genes such as FOXP1, and 
MUM1. The hallmark of the ABC DLBCL subtype is the activation of the NF-kB pathway and 
amplification of SPIB and INK4a/ARF  genes 26,38,42. The NF-kB pathways are activated by the 
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CARD11–BCL10–MALT1 (CBM) signalosome complex. The CBM complex links and 
triggers the activation of B-cell receptors with the NF-kB pathway44. The CD79A gene mutation 
and Bruton tyrosine kinase regulate the B-cell receptors signalling pathway 38,43. The 
upregulation of Bruton tyrosine kinase is associated with MYD88 mutation41,45.  
 
 
Figure 2. DLBCL subtypes based on the cell of origin. GCB and ABC subtype arise at 
different stages of B-cell development in the germinal centre. GCB arises from Centroblastic 
cells, whereas the ABC arises from Plasmablastic cells. Both these subtypes differ in the 














1.2.2 MYC and BCL2 expression 
The revised WHO classification highlight the prognostic significance of double expressors, 
which is defined as the simultaneous expression of MYC and BCL2 proteins. The suggested 
threshold for MYC protein expression is more than 40% positive tumour cells, and the threshold 
for BCL2 protein expression is more than 50%  positive tumour cells30,46.  MYC and BCL2 
double expressors have been reported in approximately 34% of DLBCL patients.  The double 
expressors have a worse prognosis than patients that express only one protein. Double expresser 
cases are more common in the ABC subtypes and this may contribute to the overall survival of 
ABC DLBCL patients47.  
 
1.2.3 EBV positive DLBCL 
EBV positive DLBCL is defined as a new disease entity30. The term “EBV positive DLBCL of 
the elderly” was used to describe EBV positive DLBCL occurring in elderly HIV negative 
patients.  However, recent studies revealed that EBV positive DLBCL does also occur in 
younger patients. Hence the term “elderly” is substituted with “not otherwise specified”48.  
There are controversies about the impact of R-CHOP on the prognosis of  EBV positive DLBCL 
patients.  Most studies show that EBV negative  DLBCL patients respond better to R-CHOP 
than EBV-positive DLBCL patients18,22,49.  
 
1.2.4 Burkitt‐like lymphoma with 11q aberrations 
Burkitt-like lymphoma with 11q aberration are rare cases characterised by Burkitt lymphoma 
features, however, they lack MYC rearrangement. Instead, they carry the 11q chromosomal 
alteration with proximal gains and telomeric losses50,51. Similar to Burkitt lymphoma, Burkitt-







1.3 Diagnosis and staging 
DLBCL is usually diagnosed from a lymph node biopsy, or excision, based upon clinical 
examination and diagnostic imaging 52. A pathologist examines tissue for B-lymphocyte 
antigens such as CD19, CD20, CD22, CD79, and CD45 53,54. Further immunohistochemical 
(IHC) stains performed CD10, BCL6, and MUM1 in order to classify the cases according to 
the revised WHO 2016 classification of DLBCL molecular subtypes, using the Hans 
algorithm30,46. DLBCL cases are classified as GCB subtype if CD 10 positive, and as ABC 
subtype if both CD10 and BCL6 negative. The expression of MUM1 is used to determine 
subtype if a case is CD10 negative and BCL6 positive. If the case is MUM 1 positive, it is 
classified as ABC subtypes and classified as GCB subtype if MUM1 negative  (figure 3)55. A 
threshold of more than 30% is used to interpret stains as either positive or negative.   
 
 
Figure 3. Hans classification of DLBCL subtypes according to the immunohistochemical 
stains. GCB-germinal centre* (Adapted from ref 55) 
 
Tissue examination also includes cytogenetic analysis, molecular genetic analysis and 
immunophenotypic analysis (Figure 4) 52,54. The cytogenic analysis (also known as 
karyotyping) is used for classifying and diagnose cancers based on chromosomal 
abnormalities53.  Fluorescence in situ hybridization (FISH) is a commonly used method for 
cytogenetic analysis and is used to detect MYC, BCL2, and BCL6 gene rearrangements in 
DLBCL56. If tissue expresses both MYC and BCL2 or BCL6, it is diagnosed as high-grade B-
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cell lymphoma (previously known as double-hit DLBCL). Triple hit (THL) lymphomas express 
all three genes (MYC, BCL2, and BCL6)56. A molecular diagnostic assay assesses the types of 
genetic alterations and the total number of alterations present in the tissue. The 
immunophenotypic analysis assesses the expression of DLBCL diagnostic markers such as 
MYC, BCL2, MUM1, Ki67, etc 39,52.  
Cancer staging is a system that describes cancer based on its invasiveness and metastasis 
57,38. 
The Positron Emission Tomography (PET) scans used to identify the size and site of the 
tumour38.  There are four cancer stages, the “early stage” which includes stages 1 and 2 and the 
“advance stage” which includes stages 3 and 4 32,45. 
 
Figure 4. Diagnostic examinations of DLCBL. Cytogenetic analysis, molecular genetic 













1.4 Treatment.   
DLBCL is usually diagnosed at “advantages stages”, therefore, the standard treatment regimen 
is rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (R-
CHOP)58,59. Although this regimen is given in twenty one day cycles for an average of six 
cycles, the length of treatment differs with individual patient 60. Approximately, 60-70% of  
DLBCL patients respond well to R-CHOP treatment, while the remainder relapse and die 59.  
Therefore, there is a need to develop effective salvage therapy for patients that relapse. The R-
CHOEP regimen (a combination of etoposide with R-CHOP) in young HIV positive patients 
have been effective 60,61. Current treatment strategies aim at developing novel drug agents with 
reduced drug toxicity and dosage for patients who cannot be cured using R-CHOP62. Recently, 
ibrutinib, a novel drug has been developed to inhibit Bruton’s tyrosine kinase, a crucial enzyme 
for the development of B-cell cancers 41.  
1.5 International prognostic index (IPI) 
The IPI is a classification system was developed to predict the prognosis of patients with 
NHLs63. This system uses five clinical parameters such as age, Ann Arbor staging, serum lactate 
dehydrogenase (LDH), oncology performance status, and extra-nodal involvement63. The 
prognosis scoring system has four risk groups. The low risk group has (0 to 1 point), low-
intermediate risk group has (2 points), high-intermediate risk group has (3 points), and high risk 
group has (4 to 5 points)63. The National Comprehensive Cancer Network (NCCN) proposed a 
better IPI system during the R-CHOP era. The NCCN-IPI uses a maximum scoring of eight and 
redefined the age, LDH, and the extranodal involvement include sites such as bone marrow, 
lungs, brain, liver, and gastrointestinal tract 64.  
1.6 Biomarker 
Biomarkers are biological molecules (such as protein, nucleic acids, specific cells or metabolite) 
that can be used to measure the of a disease severity 65. These molecules can be used as 
diagnostic, or prognostic markers for a disease 66. The discovery of protein biomarkers has 
increased over the years because proteins are the centre of almost all biological and cellular 
processes66. There are several protein biomarkers that frequently appear in literature and play a 
role in the clinical diagnosis and prognosis of DLBCL.  
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B-cell lymphoma-2 (BCL2) is an antiapoptotic protein that regulates cell death67. Mutations 
in the BCL2 gene have been identified in almost all cancers. The overexpression of BCL2 is 
regulated by MYC68. BCL2 is upregulated in the GCB subtype compared to the ABC subtype 
69. The R-CHOP regimen has altered the prognostic significance of previously studied DLBCL 
biomarkers70,71. Therefore, there are controversies about the effect of  BCL2 on DLBCL patient 
outcomes. Various studies suggest that the upregulation of BCL2 is associated with poor patient 
outcome in the ABC subtypes 67,72,73. 
Ki-67 (also known as MKI67) is a nuclear protein, clinically used to measure tumour 
proliferation of  NHL74.  Proliferation is measured by dividing all Ki-67 positive cells in a 
sample by the total number of cells present in a sample75. High Ki-67 expression is associated 
with NHL, however, in DLBCL, Ki-67 expression is regulated by MYC and TP53 proteins 
73,74,76–78.   
B-cell lymphoma 6 gene rearrangements (BCL6) is a common chromosomal abnormality in 
DLBCL that occurs at chromosome band 3q27.  BCL6  rearrangement occurs in at least 50% 
of DLBCL patients 56. BCL6 express genes that regulate the development of B-lymphocytes in 
the germinal centre 56. The expression of BCL6 is upregulated in the GCB subtype compared 
to ABC subtype39. The presence of both BCL6 and MYC rearrangements are associated with  
HIV- associated double hit lymphoma 79 
Tumour proteins p53 genetic mutations. The human P53 gene encodes for intracellular 
tumour p53 proteins72. The tumour p53 proteins are found in the cell nucleus and function to 
repair damaged DNA, by activating DNA repair proteins, as well as tumour suppressor proteins 
that prevent uncontrollable cell growth 80,81. The mutation in tumour p53 is found in 
approximately 20% of DLBCL cases. These mutations are detected by DNA sequencing and 
they lack CD19 markers 80,82–84. The expression of tumour p53 proteins is associated with MYC 
rearrangement and has a poor prognosis of DLBCL85.  Studies suggest the use of both MYC 
and tumour p53 proteins as markers for double hit lymphoma82,86.  
MYC rearrangements. MYC genes encode for transcription factor proteins located on 
chromosome band 8p24 42,68. DLBCL cases with MYC translocations and immunoglobulin 
gene loci have a poor prognosis compared to non-immunoglobulin gene DLBCL cases 42,87,88.  
Double hit lymphomas have both BCL2 and MYC gene rearrangements, and the overexpression 
of these proteins has a poor prognosis 34,68. In addition to MYC rearrangement, DLBCL cases 
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may have extra copies of MYC amplification, which have a negative impact on patient survival 
42,68.  
 1.7 Proteomics 
Proteomics is the study of the identification and characterization of the entire set of proteins 
synthesised by the cell 89.  Proteins are the centre of action for almost all cellular processes 
because they determine the structure and function of cells89. Proteins can undergo structural and 
functional changes during cellular processes, disease conditions, cellular stress or in response 
to medication. The human genome sequence has made it possible to discover and characterize 
proteins that are of diagnostic and prognostic value88. The role of proteomics in cancer research 
is to identify protein markers that can be used for early detection of specific cancers; prostate-
specific antigen is considered as a good biomarker of prostate cancer 90. The application of 
proteomic technology in cancer has led to the discovery of numerous biomarkers for many 
cancers. However, these biomarkers are not being used in clinical settings because they have 
low sensitivity and specificity91.  
Proteomic methods are labour intensive and require sample preparation, protein digestion, and 
identification 92. Proteomic analysis studies are hindered by biological sample complexity 89. A 
lot of fractionation methods have been developed to reduce sample complexity and increase the 
yield of extracted proteins in FFPE tissue specimen 89,93. The most commonly used fractionation 
methods are liquid chromatography (LC) and gel electrophoresis 89,92,94. The LC approach 
reduces sample complexity prior to mass-spec analysis by enzymatically digesting proteins to 
peptides 81. The peptide eluents are then sequenced with tandem mass spectrometry 
(MS/MS)90,95.  The major advantage of the LC approach is that the separation and identification 
of proteins are faster and simpler than 2DE electrophoresis. The 2DE gel electrophoresis is 
commonly used in quantitative proteomic studies, and it separates proteins based on the 
molecular weight or isoelectric point through a polyacrylamide gel 89. The separated protein 
fragments are then visualized on the gel using fluorescent dyes and extracted prior to detection 
on mass-spec analysis 66,89. The advantage of using a 2DE gel based proteomic approach is its 







1.7.1 Mass spectrometry in Proteomics  
Mass spectrometry is a powerful analytical tool used for the quantification and identification of 
known or unknown compounds in a sample97. The mass spectrometer uses an ion source to 
ionise proteins into gaseous ions. Generated ions are then separated and detected based on their 
mass to charge ratio (m/z)88. Mass spectrometric technology differs in the type of ion source 
and mass analysers. The commonly used ion sources are matrix assisted laser 
desorption/ionisation (MALDI) and electrospray ionisation (ESI) 91,97. There are four types of 
mass analysers, these include; time of flight (TOF), ion trap, quadrupole, and Fourier transform 
ion cyclotron resonance (FTICR)98. MALDI is a soft ionization technique and is usually 
combined with TOF analysers, whereas ESI is normally combined with ion trap analyser 99. 
During MALDI experiments a  matrix solution, (which is an acidic molecule that absorbs 
energy from the laser) is applied to tissue sections and it co-crystalizes with the analyte prior to 
ionization with laser beams 100,101. The mass spectrum is measured based on the time it takes an 
activated ion molecule to reach the ion detector.  The small ions reach the detector first and the 
larger ion reaches the detector last (figure 5) 97,102. 
 
 
Figure 5. MALDI processing steps. The laser absorbing matrix is applied to samples and it 
forms co-crystals with the sample. Laser beams are subjected to co-crystal analyte samples, 
which results in ionization and desorption of sample analyte. Finally, ions move to the ion 





1.7.2 MALDI-IMS of biological samples 
MALDI imaging mass spectrometry (IMS) is a tool used to investigate the spatial distribution 
of molecules within a tissue section103,104. The visual distribution of molecules such as 
metabolites, xenobiotic, lipids, peptides, and proteins can be determined using this 
technology105. The MALDI-IMS methods differ based on the type of matrix used during 
experiments, and the choice between matrixes depends on the type of analyte to be studied 98. 
Sinnapinic acid is a commonly used matrix to visualise the distribution of intact protein, while 
α-cyano-4-hydroxycinnamic acid (CHCA) matrix is commonly used to study peptides 106. The 
Matrix application can be done manually or automatically using a sprayer or spotter102. The 
HTX TM-Sprayer is a commonly used matrix spraying instrument and it provides a thin 
homogenous matrix layer102.  
 
MALDI-IMS technology can be applied on formalin fixed paraffin embedded tissue sections 
(FFPE), this approach maintains the histological quality of tissues and allows the detection of 
molecules with a high molecular weight such as intact proteins 107. However, formalin fixation 
of tissue causes protein-protein crosslinking due to methylation of amino acid side chains 70. 
Sever formalin treatment affects the extraction of soluble proteins and also causes DNA 
fragmentation, and this can hinder proteomic and genomic data analysis 109,110.  Despite this, 
various MALDI-IMS protocols that aim to reverse the cross-linking proteins have been 
developed 107,111. Their workflow involves the use of citrate or Tris-EDTA heat-induced antigen 
retrieval and enzymatic digestion of proteins present in FFPE tissue samples. These protocols 
have been effective in reducing sample complexity 112. Despite this,  FFPE tissue specimen are 
a valuable resource to translational proteomic studies because the samples have a well-
documented clinical data107. Although cancer research publications have taken advantage of 











2. Aims and Objectives 
The overall aim of the study is to investigate in detail, the protein distribution profile and assess 
these profiles in HIV and non-HIV related DLBCL FFPE tissue using MALDI- Imaging and 
LC-MS/MS analysis. The specific objectives were to: 
1. Prepare FFPE DLBCL tissue for proteomic analysis, 
2. determine the spatial distribution of protein signatures in tissue sections using MALDI 
IMS, 
3. identify proteins present in FFPE DLBCL tissue using liquid chromatography coupled 
with tandem mass spectrometry (LC-MS/MS), 
4. compare the protein profiles isolated from the abovementioned specimens, and 

















3. Materials and Methods 
3.1. Human Research Ethics Approval 
This study was approved by the Human Research Ethics committee of the Faculty of Health 
Science, University of Cape Town (HREC Ref: 568 /2018). 
 
3.2 Study design 
Based on previously published data 91,114, the present retrospective study consisted of 12 
archived FFPE DLBCL tissue samples [DLBCL from HIV negative patients (n=6) and DLBCL 
from HIV positive patients (n=6)]. The archived FFPE DLBCL tissue samples were further 
classified into the germinal centre B-cell-like (GCB) and activated B-cell-like (ABC) subtypes, 
according to the Hans Choi algorithm (figure 6). Human tonsil samples were used as controls 
for both HIV positive and HIV negative patients.  The HIV positive human tonsil was tested 
for p24 to confirm the HIV status, while the HIV negative human tonsil was added to compare 
any shared or common biomarkers present.  
 
Figure 6. Summary of the Study design. Study consisted of a total of 14 archived FFPE sample 
that were grouped as 6 DLBCL [HIV negative (n=3ABC; n=3 GCB)], 6 DLBCL [HIV positive 






3.3 Case selection and Data collection 
The DISA database in the Division of Anatomical Pathology/ National Health Laboratory 
Service (NHLS) was used to search for DLBCL cases. The study cases were confirmed by a 
Pathologist by re-examining the H&E histology slides. All EBV positive cases were excluded. 
Cases with plasmablastic lymphomas, Burkitt’s lymphoma and B-cell lymphomas with 
intermediate features between large B-cell lymphoma and Burkitt’s lymphoma were aslo 
excluded. 
 
3.4 Tissue preparation  
Tissue was prepared differently for MALDI-IMS and LC-MS/MS. 
3.4.1 Tissue preparation for MALDI-IMS 
Sections of 10-micron thickness were cut on a rotary microtome (LEICA RN 2125 RTS) from 
FFPE tissue blocks and transferred onto indium tin oxide coated (ITO glass) slides (Sigma-
Aldrich). The slides were then heat fixed on a hot plate at 60 °C for 10 mins. Sections were 
dewaxed in three jars of xylene (Merck, SAAR221120LC) for 5 min each.  They were then 
cleared through decreasing concentrations of ethanol (Kimix chemical and lab supplies, 
AC003) and washed well in water. This was followed by the antigen retrieval process, which 
was incorporated into our method to reverse the cross-linking of protein due to formalin fixing.  
3.4.2 Tris-EDTA Buffer Antigen Retrieval 
A pressure cooker containing Tris-EDTA [2.42g tris base (Sigma, BCBS3963V) and 0.74g 
EDTA (Sigma, SLBH4839V)] buffer solution (pH 9) was preheated until the temperature 
reached 95-100 °C.  Slides were then immersed in the pressure cooker and incubated for 90 sec. 
They were then removed, washed well in water and allowed to dry prior to trypsinization.  
3.4.3 Sample tissue digestion and matrix application 
A trypsin solution containing (5 ng/µl in 50% acetonitrile; 50 mM ammonium bicarbonate, pH 
8) was automatically sprayed (HTX TM-sprayer (Bruker) onto the tissue sections, according to 
the optimized in-house protocol with a flow rate of 0.0075 ml/min.  Twelve coatings were 
applied onto the tissue.  Spraying was carried out for 15 seconds and the drying time was 30 
seconds between each coating. The slides with digested tissue were incubated for 4hrs at 37 °C.  
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Following digestion, slides were automatically coated with α-cyano-4-hydroxycinnamic acid 
(HCCA) matrix solution containing (7g/L HCCA in 50% acetonitrile, 0.2% trifluoroacetic acid) 
at a flow rate of 0.15ml/min. The matrix application was done using an optimized HCCA setting 
on the TM-Sprayer system (HTX Technologies, LLC, Carrboro, NC, USA). The Bruker peptide 
calibration standard II was used for external calibration. A slide scanner (MF500 Reflecta High-
Resolution Tissue Scanner) was used to scan the tissue, and to ensure proper positioning of 
slides on the Bruker MALDI plate adaptor (MTP Slide Adaptor II).  
3.4.4 MALDI-IMS 
 MALDI-IMS was performed on a RapifleX MALDI TOF/TOF tissue-typer (Bruker) that had 
flexControl and fleximaging 3.0 software (Bruker Daltonik) installed within the instrument to 
control the laser beam.  The laser beams were rastered onto the tissues slides at 200 × 200 μm2 
pixel sizes. The instrument was run at positive ion reflector mode and the detection of spectral 
peaks ranged at m/z 600–3,500. The reflector voltage was set at 26.71 kV, with a suppression 
of 400 Da.  The acceleration voltage, lens voltage, and final acceleration voltage were set at 
25–22.45 kV, 8.00 kV, and 13.35 kV respectively.  
 
3.4.5 MALDI-IMS Data Acquisition 
Fleximaging v.3.0 Software (Bruker) is a software used for visualization of the spatial 
distribution of biomarkers in a tissue sample, by the automatic spectral acquisition and 
reassembling of ion images101. The spectral acquisition parameters were set for each spatial 
coordinate and these parameters were 2,500 shots per pixel area, with 200-shot increments at a 
laser frequency of 200 Hz. FlexAnalysis v.3.0 software (Bruker Daltonik) is a Bruker data 
analysis software that was used for spectral processing and baseline analysis. SCiLs Lab was 
used for statistical analyses on pooled spectral data from each sample group. 
3.4.6 SCiLs Lab data analysis.  
SCiLs Lab software (SCiLs Lab 2015b) was used for unsupervised characterization of m/z 
values in DLBCL subtypes and controls115,116.  MALDI-IMS raw data was first imported and 
converted into SCiLS H5 format. The following pre-processing data parameters were 
performed; normalization, performed at total ion count (TIC),  baseline correction, done at 
iterative convolution with (sigma 20 and 15 iterations), spectra smoothing and spatial 
segmentation, by grouping similar spectra using clustering algorithms. The Orthogonal 
Matching Pursuit algorithm was used to select peaks. This algorithm selected 15 peaks per 
28 
 
spectrum and took the consensus peaks that were in at least 1% of the considered spectra117.  
The median filtering and Chambolle algorithm (with lambda 0.5) were used to carry out image 
denoising. The denoised data were then spatially segmented using dissecting k means 
algorithm.  
3.4.7 Tissue preparation for LC-Ms/Ms 
FFPE tissue sections were cut at 10 microns, transferred onto coated slides (Histobond-
Marienfeld Lasec) and heat fixed on a hot plate at 60 °C for 10 mins. Sections were dewaxed 
and antigen retrieved as mentioned above.  Once left to dry at room temperature the tissue 
sections were scraped using scalpel blades and transferred into Eppendorf tubes.  
3.4.8 The filter-aided sample preparation (FASP)  
The FASP was performed according to previously published protocols with minor 
medication91,108,118. Briefly, all buffer washes were carried out by centrifugation at 14000g for 
15 min. Proteins were extracted (50 μL) with three rounds of 200 μL Urea (UA) buffer [8 M 
UA (Sigma, U5128) in 0.1 M Tris, pH 8.5].  To reduce the alkylation of cysteine bonds on 
extracted proteins, we incubated samples in 100 μL of iodacetamide (IAA) buffer containing 
IAA 0.05 M in UA (Sigma) for 20 min in the dark. To remove the alkylating agents, the samples 
were washed with two rounds of 100 μL UA, followed by three rounds of 100 μL of ammonium 
bicarbonate buffer (ABC buffer) (0.05M, pH 8). ABC buffer (40 μL) was added to trypsin 
(Promega) at a ratio of 1:100. Proteolysis was carried out at 37 °C for 18 hrs in a wet chamber.  
3.4.9 Desalting   
After proteolysis, peptides rich solution was eluted thrice with  50 μL of ABC buffer solution. 
Desalting was done using a homemade stage tip containing Empore Octadecyl C18 solid-phase 
extraction disk (Supelco)119.  The activation, equilibration, peptide wash, and elution of C18 
disk were done by centrifugation at 4000 rpm for 1 min.  The activation and equilibration of 
C18 disk were carried by three rinses with 80% acetonitrile (ACN), followed by three rinses 
with 2% ACN, respectively. To desalt the peptide, 10μL of the peptide-rich solution was added 
to the C18 disk, followed by three washes of 2% ACN containing 0.1% formic acid (Sigma). 
Desalted peptides were eluted into a glass insert using three rounds of 50 μL of 60% ACN, 
0.1% formic acid. The peptides were then vacuum dried in a SpeedVac vacuum concentrator 






Vacuum dried peptide in a glass insert were resuspended in 250 ng/μL of  2% ACN,  containing 
0.1% formic acid, sonicated for 3 min and transferred to a glass autosampler vial prior to mass-
spectrometer analysis. 10 μL from each sample were analysed on  Q Exactive™ Hybrid 
Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Fisher) with a flow rate of 250 nl/min. 
The M/S  was done in a data-dependent manner and the automatic scan was achieved by 
switching each M/S scan with 10 MS/MS at a scan range of at 300–1650 m/z and with a 
maximum injection time of 30 seconds. The fragmentation of ion was done at high-energy 
collision dissociation with the collision energy set at 25 NCE. The mass spectra were acquired 
at a resolution of 70 000 at a maximum integration time of 250 ms. Ion selection was done at 
an intensity threshold of 0.001 with charge exclusion of z = 1 ions. 
3.4.11 Maxquant LC-MS/MS data processing 
Maxquant (v.1.3.0.5) a quantitative proteomic software was used to process all MS raw data 
acquired from LC-MS/MS runs120. Peptide identification was done using the andromeda search 
engine, which uses a human proteome to search peptides against the International Protein Index 
(IPI human version 3.87). Trypsin and Carbamidomethylation were selected as enzyme 
specification and as a fixed modification during the peptide search. The false discovery rate 
(FDR) for both peptides and proteins was set at 1%. Label-free quantitation (LFQ) on at least 
one peptide per protein was performed using the MaxLFQ algorithm and the re-quantify 
function. Minimum cut off for peptide length was set at seven amino acids, and maximum 
permissible missed cleavage was set at 2. All the LFQ data obtained from Maxquant was then 
imported into the Perseus software (version 1.6.10.43) for further statistical analysis and 
visualization by hierarchical clustering.  
 
3.4.12 Perseus: Data processing and Normalization  
Perseus is a proteomic software used for the statistical analysis of “omics” data and for the 
interpretation of protein quantification121. The Maxquant output file was first converted into a 
text (ProteinGroup*.txt) format and loaded to Perseus software (version 1.6.10.43). The LQF 
intensities from all the samples were loaded as the main columns. The data processing 
parameters were used to filter, transform and group sample proteins.  Proteins that were only 
identified by site, reverse protein, and potential protein contaminants were filtered out. Samples 
were grouped according to their replicates and the transformation of data was done using the 
formula “log2(x)”. Data transformation was done in order to normalize the data prior to 
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applications of the statistical test.  A two-sample t-test (-log transformation P-values) set at a 
threshold of 0.05 (5% probability error) was performed to determine which proteins were 
significantly different among the DLBCL subtypes.  The differential expression levels were 
visualised by hierarchical clustering. Appendix H, figure 26 summarises the data processing 
pipeline.  
 
3.4.13 Haematoxylin & Eosin (H&E) Staining for the two tonsil controls. 
Sections of 3 microns were prepared from archived FFPE tissue blocks and transferred onto 
normal microscopic slides (Lasec).  After being heat fixed on a hot plate at 60 °C for 10 mins 
sections were dewaxed through three jars of xylene (Merck, SAAR221120LC) for 5 min each. 
They were then passed through decreasing concentrations of ethanol (Kimix chemical and lab 
supplies, AC003) (100, 95, and 70%) followed by washing well in water. Slides were then 
stained with Haematoxylin (Mayers) for 5 min and blued in ammoniated water. After washing 
well in water, the slides were placed in Eosin (MERCK) for 2 minutes.   Finally, the slides were 





4. Results  
4.1 Clinical and biological parameters 
This study had 12 DLBCL cases and 2 human tonsil controls diagnosed from 2009-2011. These 
cases were retrieved using the NHLS database, however, only 11 patient folders were located 
from Groote Schuur hospital (GSH) (table 1). The overall age of DLBCL patients by the time 
they were diagnosed ranged from 18 to 73 years, with a median age of 48 years.  The number 
of HIV positive males was 5 and their age at the time of diagnosis ranged from 18 to 54 years, 
with a median age of 40 years. There were five HIV negative females and their age by the time 
of diagnosis ranged from 37 to 73 years, with a median age of 55 years. All the cases presented 
with extranodal lymphomas. The common extranodal sites in both HIV positive and HIV 
negative cases were submandibular, axilla, mesentery, supraclavicular, testis, and inguinal 
(Appendix I, table 9). We only included EBV negative cases in this study, because EBV positive 
DLBCL is another disease entity of lymphoma.  
Table 1. The clinical and biological parameters of DLBCL from HIV positive and HIV negative 
patient study cohort.  
 
Case (n=12) Control 
(n=2) 
      Age range (median)  
            18 to 73 (48) 
HIV (-) Age range 
(median) 
Range (37 to 73)  
Median (55) 
Unknown 
HIV (+) Age range 
(median) 
Range (18 to 54) 
Median (40) 
Gender M 6 (5 HIV(+):1 HIV(-))   - 
F 5 all HIV(-)  - 
Unknown 1  - 
Classes (HIV Status) ABC (Pos: Neg) 6(3:3) N/A (1:1) 
GCB (Pos: Neg) 6(3:3) 
EBV status Positive 0 0 
Negative 12 2 
Site Nodal 0 0 
Extra-nodal 11 2 
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The patient folder for one case was not found. Hence the gender, age, and lymph node site were 
not recorded.  
 
4.2 MALDI IMS results: Principle Component Analysis of Mass-
spectral peaks between DLBCL cases and controls were distinguished 
by MALDI-IMS.  
 
4.2.1 Principle Component Analysis (PCA) Clustering between GCB (HIV+) 
and HIV (+) control 
The FFPE tissue region of interests (ROIs) from HIV (+) GCB DLBCL subtype and HIV (+) 
control were marked by the pathologist on H&E slides and were superimposed on scanned ITO 
slides (Appendix C.1, figure 17and 18). SCiLs lab software was used to superimpose the 
marked ROIs on scanned ITO slides (figure 7A). The average spectra of the ions were observed, 
and the peak picking function identified 457 ions in the range of m/z 606-3500 (figure 7B). The 
PCA plots were used to differentiate extracted MALDI  mass spectra from three  HIV (+) GCB 
DLBCL samples and one HIV (+) control. The PCA score plot indicated four distinct clusters 
between the ion patterns of the mass spectra of the three GCB DLBCL HIV (+) samples and 
one HIV (+) control. The HIV(+) control (indicated in yellow) did not cluster with any of the 
HIV (+) GCB DLBCL samples (figure 7C). The loading plot of the PCA analysis provided 
information regarding the contribution of each ion signal to the variance covered by each 
principal component PCA1 and PCA2. There were 21 different ion signals that contributed to 




Figure 7. PCA analysis on GCB(HIV+) and (HIV+) control MADLI-IMS data set. (A)  
Stack view of scanned GCB (HIV+) cases (green, blue and purple) and (HIV+) control 
(Yellow). (B) Average spectra of the GCB(HIV+) cases and (HIV+) control clusters in the m/z 
range 606-3500. (C) PCA score plot indicated distinct clusters.  (D) PCA loading plot indicated 
the contribution of each ion signal to the variance covered by PCA1 and PCA2. 
 
4.2.2 PCA clustering between GCB DLBCL HIV(-) and HIV(-) control 
The marked ROIs from three GCB DLBCL HIV (-) samples and HIV (-) control samples, were 
loaded onto SCiLs lab software (figure 8A). The average spectra of the ions were observed, and 
the peak picking function identified 364 ions in the range of m/z 600-3200 (figure 8B). The 
PCA score plot indicated three distinct clusters between the ion patterns of the mass spectra of 
the three GCB DLBCL HIV (-) samples and one HIV (-) control (figure 8C). Samples GCB 
HIV (-) 1 indicated in yellow, and GCB HIV (-) 2 indicated in green clustered together. The 
loading plot observed 9 different ion signals that contributed to the variance covered by PCA1 










Figure 8. PCA analysis on GCB(HIV-) and (HIV-) control MADLI-IMS data set. (A)  Stack 
view of Scanned GCB (HIV-) cases (yellow, green and blue) and (HIV-) control (purple). (B) 
Average spectra of the GCB(HIV-) cases and (HIV-) control clusters in the m/z range 600–
3500 (C) Score (spectra) plotted against the first two components. (D) Loadings (m/z values) 
plotted against the first two components. 
 
4.2.3 PCA analysis between ABC DLBCL HIV (+) and HIV (+) control 
The marked ROIs from ABC DLBCL HIV (+) and HIV (+) control were loaded onto SCiLs 
lab software (figure 9A). The spectral peaks identified  335 ions in the range of m/z 607-1405 
(figure 9B).  The PCA score plot result indicated three clusters between the ion patterns of the 
mass spectra of the three ABC HIV (-) samples and HIV(-) control. The HIV (+) control 
(indicated in purple) and ABC DLBCL (HIV+) -2 (indicated in blue) clustered together (figure 
9C). There were 11 different ion signals that contributed to the variance covered by PCA1 and 








Figure 9. PCA analysis on ABC(HIV+) and (HIV+) control MADLI-IMS data. (A)  Stack 
view of Scanned ABC (HIV+) cases (green, blue and yellow) and (HIV+) control (purple). (B) 
Average spectral peak of the ABC(HIV+) cases and (HIV+) control clusters in the m/z range 
607–1405 (C) PCA score (spectra) plotted against components 1 and 2. (D) Loadings (m/z 















4.2.4 PCA analysis between ABC (HIV-) and HIV (-) control 
The ROIs from three ABC DLBCL HIV(-) samples and one HIV (-) control sample were loaded 
onto SCiLs lab software (figure 10A). The spectral peaks identified  312 ions in the range of 
m/z 606-2519 (figure 10B). The PCA score plot showed similarities between ABC (HIV -) 
sample 1 (indicated in yellow) and ABC (HIV-) sample 2 (indicated in green) (figure 10C).      
A distinct separation was observed between the ion patterns of the mass spectra of the ABC 
(HIV-) samples 1, 2 and 3 (indicated in yellow, green, and purple respectively) and  HIV (-) 
control (indicated in blue). The loading plot showed 9 different ion signals that contributed to 
the variance covered by PCA1 and PCA2 (figure 10D). 
 
Figure 10. PCA analysis on ABC(HIV-) and (HIV-) control MADLI-IMS data set. (A) 
Stack view of scanned ABC (HIV-) samples (ABC sample1 yellow, ABC sample 2 green and 
ABC sample 3 purple) and (HIV-) control (blue). (B) The average spectral peak of the 
ABC(HIV-) cases and (HIV-) control m/x range 606-2519. (C) PCA score (spectra) plotted 








 4.2.5 Exclusive ion mass (m/z) values identified in DLBCL cases 
The peak detection function on the MALDI-IMS instrument identified 50 exclusive ion signals 
that distinguished DLBCL subtypes (appendix D, table 7). An online Venn diagram plotting 
software (http:/bioinformatics.psb.ugent.be), was used to visualize the exclusive ions among 
the different DLBCL subtypes. Exclusive ions found in each subtype were 11 ions for ABC 
HIV (+), in the range m/z 627-1030, 9 ions for ABC HIV (-), in the range m/z 643-2042, 21 
ions for GCB HIV (+), in the range m/z 649-2086 and 9 ions for GCB HIV (-) in the range m/z 
643-3025 (Figure 11).  
 
Figure 11. Venn diagram showing a possible relationship of discovered ion signals among 
DLBCL cases;[HIV (-) ABC and GCB; HIV (+) ABC and GCB]. As a result, none of the ion 
signals were common among the DLBCL cases. 
     
We assessed the distribution of the ion with the highest intensity in the subtypes and the controls 
(Appendix C.2, figure 19). m/z 936.255 had the highest intensity in the  HIV (-) control 
compared to the HIV (+) control and the DLBCL subtypes (Appendix C.2, figure 19 A,B,C). 
the AUC values was 0.936, this shows that the test analysis was able to identify m/z 936.255 




4.3 LC-MS/MS data analysis 
4.3.1 LC-MS/MS data distribution 
FFPE tissues from 12 archived samples and 2 controls were subjected to LC-MS/MS based 
proteomic analysis. The Perseus software (version 1.6.10.43) was used to process and 
statistically analyse the data. After data processing, the protein entries reduced from 204 to 88. 
This meant that there were 88 proteins among all 14 DLBCL FFPE tissue specimens. All the 
potential contaminant proteins and reverse proteins were filtered out during data processing. 
An intensity box plot (figure 12) was generated to verify the distribution of the data. The protein 
intensities of each DLBCL subtype were not normally distributed, this was due to insufficient 
data and outliers of some protein intensities being extremely high or low in some samples. E.g. 
when actin cytoplasmic 1 was randomly selected (indicated in green), we observed an extremely 
high outlier in almost all the DLBCL samples except in ABCP2 and GCBP2 samples. The 
isoform2 of transcription intermediary factor 1 protein (indicated in red) was an extremely low 
outlier in samples ABCN1, ABCN3, ABCP1, and ABCP2. However, this protein was not 
present in other samples. Finally, the intensity of triosephosphate isomerase protein (indicated 







Figure 12. Intensity Boxplot showing the spread of data after processing and 
normalization. HIV negative DLBCL ABC subtype (ABCN1=sample 1 and ABCN3= sample 
3). HIV positive DLBCL ABC subtype (ABCP1= sample 1 and ABCP2= sample 2). HIV 
negative DLBCL GCB subtype (GCBN2= sample 2). HIV positive GCB subtype (GCBP 1= 
sample 1 and GCB2= sample 2).  HIV negative control (HNC) sample. Proteins intensities for 
Actin cytoplasmic 1 (green), Isoform2 of transcription intermediary factor 1 (red)and Isoform2 















4.3.2 Experimental quality check 
 A multiple scatter plot (figure 13) was generated to determine if there was a linear correlation 
between the DLBCL samples and controls. The linear correlation was considered to be 
moderate if the Pearson correlation was (0.5< r <0.7). A strong linear correlation was 
considered to be strong if  (r> 0.7) 69 and weak if (r<0.3). The overall linear correlation between 
variables was generally weak (r<0.3). There was a moderate positive linear relationship among 
samples (ABCN1 and ABCN3 ;r=0.588), (ABCP2 and ABCN1 r=0.562), (GCBP2 and 
ABCN1; r=0.653), (GCBP2 and ABCN3; r=0.525) and (GCBP2 and ABCP1; r=0.552).  
 
 
Figure 13: Multiple Scatter plots illustrate the relationship between DLBCL cases and 
controls.  The correlation coefficient of (r < 0.3) and the lines are difficult to detect. While 
there was a moderate correlation between (ABCN1 and ABCN3 specimen ,r=0.588), (ABCP2 
and ABCN1 specimen, r=0.562), (GCBP2 and ABCN1 specimen, r=0.653), (GCBP2 and 




4.3.3 Identification of potential biomarkers using Perseus 
Taking each sample individually, we identified 88 and 32 proteins in samples ABCN1 and 
ABCN3, respectively. Similarly, the number of proteins in samples ABCP1 and ABCP2 were 
52 and 45 respectively. Only 59 proteins were identified in the GCBN2 sample. A total of 21 
and 41 proteins were identified in GCBP1 and GCBP2 samples, respectively (figure 14). In the 
HIV negative control (HNC),  31 proteins were identified, whilst no proteins were identified in 
samples ABCN2, ABCP3, GCBN1, GCBN3, and HPC. Further statistical analysis was carried 
out on identified proteins. Appendix J, table 10 summarizes the total number of proteins 
identified in this study.  
 
 
Figure 1414. The total number of proteins found in all the DLBCL subtypes. HIV negative 
DLBCL ABC subtype (ABCN1=sample 1 and ABCN3= sample 3). HIV positive DLBCL ABC 
subtype (ABCP1= sample 1 and ABCP2= sample 2). HIV negative DLBCL GCB subtype 






4.3.4 The identification of significantly differentially expressed proteins between 
HIV negative DLBCL ABC subtype (ABCN) and HIV positive DLBCL ABC 
(ABCP) subtypes. 
A two-sample t-test (-log transformation P-values) at a threshold of 0.05 (5% probability error), 
identified human fructose-bisphosphate aldolase C (p value=1,47738) as the only differentially 
expressed proteins between ABCN and ABCP subtypes (figure 15). The KEGG pathway 
analysis revealed the involvement of fructose-bisphosphate aldolase C in the glycolytic 
pathway. A similar test was performed between the HVNC and ABCN specimens and there 
were no differentially expressed proteins.  
 
Figure 15. Two-sample t-test Statistical analysis for ABCN and ABCP. The symbol '+’ 
indicates statistical significance with respect to the specified threshold of 0.05 (5% probability 
error).  
4.3.5 The identification of significantly differentially expressed proteins between 
HIV negative DLBCL GCB subtype (GCBN) and HIV positive DLBCL GCB 
(GCBP) subtypes.  
A two-sample student t-test set at a threshold of 0.05 (5% probability error) was also applied to 
identify differentially expressed proteins between the GCBN and GCBP subtypes. There were 
no differentially expressed proteins between  GCBN and GCBP subtypes (Appendix G, figure 
22). A similar test was performed between the HVNC and GCBN  specimens and there were 









4.3.6 Hierarchical clustering heatmap  
The hierarchical clustering of proteins was done using the Euclidean distance method to 
visualize the differentially expressed protein in DLBCL subtypes and controls. The high and 
low protein expressions were indicated in red and green respectively (figure 16).  We used a 
filtering strategy that required at least one protein to appear in 9 of the 14 specimens to be 
included for subsequent analyses.  By comparing these proteins, we observed 6 differentially 
expressed among the DLBCL subtypes and controls (appendix E, table 8). These proteins were 
Tubulin alpha, ATP synthase, Enolase, Actin, Pyruvate kinase, and Ig kappa chain. Most of 
these proteins were part of the glycolytic pathway and ATP synthesis.  
 
 
Figure 16. Hierarchical clustering heatmap of differentially expressed proteins among 
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FFPE tissue specimens are a valuable resource for translational proteomic studies because they 
provide archived patient samples, and well-documented clinical data (Table 1). Our findings 
regarding the patient's age showed a median age of 40 years for HIV positive DLBCL patients, 
which confirms previous studies that reported a median age of diagnosis for HIV-associated 
DLBCL to range from 30 to 49 years 122,123. Although studies show an increase in the number 
of HIV positive females in South Africa, with studies showing predominance of HIV positive 
females, our study only had HIV negative females 124,125.  
The PCA is the most commonly used statistical method used to visualize the overall variability 
of a data set (figure 7,8,9, and 10)126. The dimensionality of the date set is reduced to a 2D or 
3D coordinate system, which uses dots to represent the mass spectrum. The spectra with similar 
features cluster together and the differences between sample groups are visualized in this 
coordinate system. The first two principal components (PCA1 and PCA2) in the 2D plot 
provides more than 80% of the total variance between the samples126.  Using the 2D scores plot, 
we observed differences in both the HIV negative and positive GCB DLBCL samples (figure 
7C and 8C). This suggested differences in the mass spectra ions between the diseased samples 
(DLBCL cases) and the normal tissue control (human tonsil). There was one sample in ABC 
DLBCL samples (both HIV positive and negative) that clustered together with the control 
sample (figure 9C and 10C). This clustering suggests that the ABC DLBCL samples had similar 
features to the control sample or that the largest source of variation among DLBCL cases and 
controls was similar.  The loading plots of the PCA was used to visualize the ion signals with 
significant differences between the DLBCL samples and controls126. The significantly different 
ion signals were observed among the DLBCL samples and controls (figure 7D, 8D, 9D, and 
10D). The significantly different ion signals were those that contributed to the variance covered 
by principle component 1 and component 2 in the PCA loading plots. To further validate this, 
we used the Venn diagram to visualize the distribution of the ion signal among the DLBCL 
subtypes, and there were 50 exclusive ion signals (figure 11). The number of exclusive ion 
signals observed in each of the DLBCL subtypes using a Venn diagram was similar to the total 
number of ion signals observed in the PCA loading plots.   
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FFPE tissue samples are not only used for the discovery of biomarkers but can also be used to 
understand molecular processes and pathways of cancer or other diseases107. We successfully 
applied LC-MS/MS to a total of 14 FFPE tissue samples and we identified a total of 88 proteins 
among all 14 FFPE tissue samples (Appendix E, table 8). The FFPE tissue processing method 
and LC-MS/MS strategies used herein have been performed in other published studies 84,122,123.  
We used a filtering strategy that required at least one protein to appear in 9 of 14 specimens to 
be included for subsequent analyses. By comparing these proteins, there were 6 statistically 
significant proteins that were differentially expressed among the DLBCL subtypes and controls. 
These proteins were Tubulin alpha, ATP synthase, Enolase, Actin, Pyruvate kinase, and Ig 
kappa chain (figure 16). The majority of the proteins identified belonged to the glycolysis, ATP 
synthesis, and cellular movement.  Glycolysis is a metabolic pathway by which cells breakdown 
glucose to generate their own energy in a form of ATP127. The production of ATP is essential 
for the synthesis of proteins. The synthesised proteins play a role in the regulation of cellular 
processes, and in providing cellular structure and movement 127,128.  
Glycolytic proteins are usually overexpressed in cancer cells due to the increased cellular 
energy requirements during cell proliferation 129. The glycolytic enzymes identified in our study 
were pyruvate kinase and alpha enolase. Pyruvate kinase is an enzyme involved in the last 
stages of glycolysis. It catalysis the formation of ATP and pyruvate from adenosine diphosphate 
(ADP), as phosphoenolpyruvate undergoes dephosphorylation130.  The hallmark of cancer is 
increased glycolytic levels81. Previous studies observed an upregulation of pyruvate kinase in 
DLBCLs and other cancers 131–133, which is due to increased glycolysis. Warburg effect is the 
hallmark of cancer, whereby cancer cells undergo increased glycolysis to produce energy 
followed by lactic acid fermentation in the cytosol132. During these processes, pyruvate kinase 
is overexpressed and it catalyses the production of ATP during aerobic glycolysis 132. Pyruvate 
kinase gives the tumour cells growth advantage and enables them to adapt and survive the 
tumour microenvironment134.  
Enolase is an enzymatic protein that catalyses the conversion of  2-phosphoglycerate (2-PG) to 
phosphoenolpyruvate (PEP)130. Various studies found enolase to play a role in metastasis and 
immune invasion by enhancing proteolytic activity through function as a plasminogen 
receptor130,131.  In lung cancer, the upregulation of enolase was found to promote cell glycolysis, 
growth, migration, and invasion through FAK-mediated PI3K/AKT pathway135. Increased 
enolase expression was found to stimulate glycolysis, and this enhances resistance to 
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chemotherapy in gastric cancer patients. Therefore, this suggests the use of enolase as a 
biomarker to predict drug resistance and the overall survival of gastric cancer patients 136.  
ATP synthase is an enzyme that plays a role in ATP synthesis and catalyses the oxidative 
phosphorylation during the respiratory process.  We found ATP synthase to be downregulated 
in our study (table 2) which confirms previous findings from other studies 137. Various studies 
found ATP synthase to be downregulated in almost all human cancers when compared with its 
expression in normal tissues130,137. Human cancers also upregulate the ATPase inhibitory factor 
1 (IF1), which is the physiological inhibitor of the H+ -ATP synthase. The overexpression of 
IF1 reprograms energy metabolism to enhanced glycolysis by limiting ATP production by the 
H+-ATP synthase. Furthermore, the IF1-mediated inhibition of the H+ -ATP synthase promotes 
mitochondrial ROS, which regulates signalling pathways that favour cellular proliferation, 
activation of antioxidant defences, cell death resistance, and modulation of the tissue immune 
response, favouring the acquisition of several cancer traits 137.   
In addition, we also found actin to be upregulated in our study, similar to other studies, that 
found actin as a key protein that provides cellular motility during the metastasis of cancer 138,139.  
Tubulin is a protein that polymerized into filaments that form microtubules140. Microtubules 
are involved in cellular movement, intracellular trafficking, and mitosis. In cancer, the tubulin 
proteins are targets of the tubulin-binding chemotherapeutics, which supress the mitotic spindle 
to cause mitotic arrest and cell death. The over expression of different types of tubulin has been 
reported in a range of cancers. This expression is often correlated with poor prognosis and 
chemotherapy resistance in different types of cancers141. Tubulins and microtubules have been 
found to regulate mitochondrial metabolism. A recent study demonstrated that tubulin is 
capable of inter- acting with, and blocking the VDAC, thereby regulating ATP and metabolite 
compartmentalization and contributing to the War- burg effect142.  
Immunoglobulin kappa chain (IGKC) is a protein subunit of an antibody that is produced by 
immune cells. It links together with the heavy chain to form immunoglobulin  (also known as 
antibodies)87. The IGKC is an immunological biomarker of prognosis and response to therapy 
in human cancers143.  Little is known about the expression of IGKC in cancer cells. Various 
studies suggest that the secretion of IGKC by cancer cells has an unidentified capacity to 
promote cancer cell growth and survival144.  
Fructose-bisphosphate aldolase C (also known as aldolase C) was the only statistically different 
protein expressed between the ABC (HIV-) and ABC HIV (+) subtypes (p=1,47738). This 
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protein functions as an enzyme in glycolysis that splits aldol, fructose 1,6-bisphosphate, into 
the triose phosphates dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate 
(G3P) during glycolysis and gluconeogenesis 130. Aldolase is differentially expressed in human 
tissues and has observed in different types of human cancers130,132. A previous study found 
aldolase enzymes to be upregulated during metastasis of  Colorectal Adenocarcinoma135. 
Another study found aldolase enzymes especially aldolase A to be overexpressed in colon 
cancer145.  Therefore, the expression of aldolase proteins is associated with an increased level 
of glycolysis and poor overall survival of cancer patients146. Aldolase has been validated though 
“-omics” database as a prognostic marker for different types of human cancers147. The clinical 
significance of aldolase C has not yet been studied in the context of DLBCL.  
There were no differentially expressed proteins identified between both HIV negative and 
positive GCB DLBCL subtype. This may be caused by protein degradation during 
experiments148.   
Although we were able to successfully identify proteins using FFPE tissue, formalin fixation 
preparation conditions present a barrier that limits protein identification107. Protein-protein 
crosslinking occurs during formalin fixation. Chemically, during fixation formalin causes the 
methylation of amino acid side chains which forms a methylene bridge 70. This may hinder the 
extraction of soluble proteins from FFPE tissue specimen 109,110. Prolonged formalin fixation, 
results in increased protein-protein crosslinks which affect genomic and proteomic 
analysis109,110. Proteomic studies are limited by biological sample complexity, this may affect 
the analytical depth of the proteomic study89. In order to reduce sample complexity in our study, 
we used the FASP (Filter Aided sample preparation) method for FFPE sample preparation. The 
FASP protocol has been successfully applied by other researchers to FFPE tissue specimens 







Using proteomic techniques, we identified and visualized differentially expressed protein in 
DLBCL subtypes and controls. The majority of these proteins belonged to glycolysis, ATP 
synthesis, and cellular movement. Fructose-bisphosphate aldolase C was the only significantly 
differentially expressed proteins between HIV negative ABC DLBCL and  HIV positive ABC  
DLBCL subtypes. Suggesting its involvement in glycolysis which is a hallmark of cancer. 
Although, the aims and objectives of this study were archived. However, more research needs 
to study the clinicopathological correlation of HIV negative and HIV positive DLBCL with 
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8.1 Appendix A: Optimization experiments of MALDI-IMS 
experiments  
Tissue sectioning 
After tissue sectioning the slides were placed on a hearing block for 10, minutes at 60°C.  the 
slides were dewaxed with 3 serial washes of xylene and graded alcohol. The slides were finally 
washed with tap water to remove any access alcohol.  
Slide coating protocol  
• Mix 1:1 poly-L-lysine with water in an Eppendorf tube  
• Add 1 µl of IGEPAL per 1.5 ml  
• Streak out 2 drops of a Pasteur pipette onto an ITO coated slide using a tongue depressor  
• Dry slide for 15 min on 60°C 
 
Antigen retrieval  
Tris -EDTA buffer solution was prepared with 2.42g Tris Base (Sigma, BCBS3963V) and 0.74g 
EDTA (Sigma, SLBH4839V) in 2 l of distilled water. The slides were pressure cooked for 1 
min 30 seconds and air-dried overnight prior to processing.  
 
Table 3. COMPOSITION OF SOLUTIONS 
Haematoxylin 1g  
Potassium/ammonium 
aluminium 50g  
Sodium iodate 0,2g  
Citric acid 1g  
Chloral hydrate 50g  





Table 4. REAGENT SUPPLIERS 
Name Supplier 
Trifluoroacetic acid Sigma 
Acetonitrile Merck 
Water, proteomics grade Fluka 
HCCA matrix Bruker 
Absolute Ethanol Millipore 
Trypsin Promeg 
Acetonitrile Sigma 
ITO slides Sigma 
Poly-L-Lysine Sigma 
Ammonium Bicarbonate Sigma-Aldrich 
ITO coated slides Sigma-Aldrich 
Xylene merck 
Tris Sigma 
EDTA  Merck 
Tween  Sigma 
 
Matrix: Sinnapinic acid  
The sinnapinc acid (SA) matrix (0.05g/l in 70% acetonitrile, 0.1 trifluoroacetic acid) was 
automatically spotted onto the tissue section using the SA spraying method on the HTX control 
software on the laptop which was connected to the HTX TM-sprayer.  Teaching points were 
marked around the tissue section of interest using a tippex. A small section of the matrix was 
wiped off from the slide with 70% ethanol which was used to put the calibration spot.   In an 
Eppendorf tube, a calibration standard mixture containing 6 µm/l protein standard was prepared 
(1.5 µm/l insulin (bovin), 10 µm/l apomyoglobin (equine), 10 µm cytochrome c (equine)  with 
6 µm/l SA matrix. Then 1µl of the calibration standard mixture was used create a spot on the 





Teaching points were created on the slide by drawing an X mark in the region around the 
tissue.   
• Draw X marks on the corners of the tissue slide making sure the tissue is within the 
marks (this will be used as teaching points downstream) 
• Create a clean area on the slide by wiping off the matrix with 100% methanol for 
addition of the calibration spot 
• Pick 1uL of the standards and matrix mixture and make a spot on the tissue. Allow to 
dry and make at least 4 layers. Then allow to dry completely. 
• Position the slide into the slide holder and insert into the scanner 
• Open CyberviewX application 
• Scan settings should be at 3200dpi and 8-bit colour 
• Open scan>prescan>prescan current frame 
• Adjust the view area on the prescanned image 
• Then click scan>scan current frame 
• Open the new image that is automatically saved in D:data\imageScanner open the image 
with windows picture viewer 




• Insert slide into Rapilflex slide holder 
• Use a 96well plate lid to provide the orientation within the flex control environment 
• Mark the tissue orientation where the X marks locations are on the 96 well plate lid 
• Also highlight the location where the calibration spot is 
• Place the cover lid on top of MTP384 ground steel plate and use it for orientation 
• Open the flex control 
• Insert the slide carrier into rapiflex 
• Select the correct geometry (MTP slide adaptor II) 
• Select method (LP_2-20kDa.par) 
• Press the insert button  
• Navigate to the calibration spot and press start to shoot. 
• If the spectra is quality “add” repeat 3 times  
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Display sum spectra 
• At the calibration tab select the relevant mass control list of calibrations. For proteins 
select “protein1Calib standard” 
• Click on automatic assign and click on apply when at least 3 mass standards are assigned 
• Open flex imaging 
• Set up new imaging run 
• Assign a name to your image run 
• Acquisition settings raster 200um, method LP_2-20kDa.par 
• Processing options select “perform smoothing” and perform base line subtraction 
• Select the image that was scanned 
• Create 3 teaching points on image at the fleximaging guided by the X marks that had 
been made 
• On the flex imaging create ROIs either add polygon or rectangle around the areas where 
you want to analyse 
• Draw the ROIs with the mouse then click “start automatic run” navigate to flex control 
and wait until the image run is complete 
• Navigate back to flex imaging and click load results. The data will be saved in D:\data 
drive 
• Inspect the loaded spectra 
 
MALDI data analysis with ScilsLab 
• Plug in scilslab software dongle  
• Open the SCiLs Lab from the icon 
• To make independent data sets Load the dataset into the SCiLs Lab by clicking on 
File>New>select TOF> Next 
• Use the red+ to add the data sets you need to analyze  
• To combine two or more data sets into one .sl file click on New (combine data sets into 
a new .sl file 
• Select TOF as the instrument type> next>click on the red+ to navigate to the data sets 
stored in D:data file keeps adding as many as the data sets you want to compare  
• When all the data sets have been imported then you can conduct downstream analysis 




To create box plots and correlation plots 
• Select the region of interested M/Z range and create an M/Z image 
• When the M/Z image have been created click on the intensity box plot tab 
• View the plots based on the selected region and the m/z interval image created 
• Use this to compare different experiments based on the image runs that were loaded into 
the SCiLs Lab 
Discovery of M/Z markers annotated on the tissue  
Follow the online SCiLs Lab resource to conduct analysis of the imaging data [ 
https://scils.de/mediacenter/ ] 
 
8.2 Appendix B: LC-MS/MS experiments  
2.1 Materials 
Table 5. Solutions and Reagents 
Xylene 
Absolute ethanol 
Lysis solution (LS): 0.1 M Tris-HCl, pH 8.0, 0.1 M DTT 
20% (w/v) solution of SDS in water 
Urea (UA) solution: 8 M urea (Sigma, U5128) in 0.1 M Tris/HCl pH 8.5 
IAA solution: 0.05 M iodoacetamide in UA 
Trypsin, stock 0.4 µg/µL 
Ammonium bicarbonate (ABC) solution: 0.05M NH4HCO3 in water 











Table 6. Equipment 
Ultra-Turrax blender (T 10 basic Ultra, IKA, Staufen, Germany). 
Branson Sonifier (Heinemann, Schwäbisch Gmünd, Germany) 
Vivacon 500 (Sartorius Stedim Biotech) 
Refrigerated bench-top centrifuge, set to 18°C 
Incubator set to 37°C 
Wet chamber with a rack for Eppendorf tubes 
Heating block with agitation, set to 99°C 
Centrifugal vacuum-dryer (Speed-Vac) 
 
2. 2 FASP Protocol 
• Incubate FFPE tissues slices in 1 mL of xylene in an Eppendorf-type tube with gentle 
agitation at room temperature for 5 min. 
• Remove the solution, add 1 mL of xylene and incubate as in (1). 
• Remove the solution and repeat steps 1 and 2 in each using 1 mL of absolute ethanol. 
• Remove ethanol and vacuum-dry the sample.  
• Mix the dried tissue with LS in a tissue to buffer ratio of 1:20 and homogenize on ice 
using the disperser for 3 min.   
• Sonicate the suspension on ice for 3 min. (output control 5; duty cycle 20%) 
• Add 20% SDS to the suspension to a final concentration of 4%. 
• Incubate in a heating block with agitation (600 rpm) at 99°C for 60 min. 
• Remove the tube from the heating block and let it slowly chill to the room temperature. 
• Centrifuge the extract at 16,000 × g for 10 min.   
• mix up to 50 µL of the clarified lysate with 200 µL of UA in the filter unit and centrifuge 
at 14,000 × g for 30 min. 
• Add 200 µL of UA to the filter unit and centrifuge at 14,000 × g for 20 min. 
• Discard the flow-through form the collection tube. 
69 
 
• Add 100 µL IAA solution and mix at 600 rpm in a thermo-mixer for 1 min and incubate 
without mixing for 20 min. 
• Centrifuge the filter units at 14,000 × g for 10 min. 
• Add 100 µL of UA to the filter unit and centrifuge at 14,000 × g for 15 min. Repeat this 
step twice. 
• Add 100 µL of ABC to the filter unit and centrifuge at 14,000 × g for 10 min. Repeat 
this step twice. 
• Add 40 µL ABC with trypsin (enzyme to protein ratio 1:100) or another protease and 
mix at 600 rpm in thermo-mixer for 1 min. 
• Incubate the units in a wet chamber at 37°C for 4 -18 h. 
• Transfer the filter units to new collection tubes. 
• Centrifuge the filter units at 14,000 × g for 10 min. 
• Add 50 µL of ABC and centrifuge the filter units at 14,000 × g for 10 min. 





8.3 Appendix C.1: Region of interest (ROIs) drawn on H&E slides and 
scanned with MALDI-IMS 
8.3.1 Region of interest (ROIs) drawn on H&E slides and scanned with MALDI-
IMS  
 
Figure 17 ROIs drawn on ABC HIV Negative and GCB HIV negative tissue slides. 
 




8.3. Appendix C.2: Spatial distribution of the ion with the highest intensity  
 
 
Figure 19. Spatial distribution of the selected m/z 0.967. (A) m/z 936.255 had the highly 
distributed on the HIV (-) control (indicated in red). (B) intensity box plot of the selected m/x 
values. (C) Average peak MALDI mass spectra intensity of all the samples. (D) Receiver  















8.3.3 Appendix C.3 ROIS DRAWN IN MALDI IMS ANALYSIS 
 
 
Figure 20. Spatial distribution of ions discriminating Control tissue (CTL), and Sample 1; GC 
HIV (+), Sample 2; ABC HIV (-) of the MALDI-imaging data.  The m/z-value 599.799 ± 
0,067% (AUC=0.973) is abundant in the CTL tissue.  Visualization was performed in SCiLS 
 
8.4 Appendix D: Exclusive ion mass (m/z) values identified in DLBCL 
cases 
Table 7 The number of different ion mass (m/z) values identified in DLBCL cases. 
HIV positive DLBCL 
GCB 
Ion mass(m/z) 
HIV negative DLBCL 
GCB 
Ion mass(m/z) 
HIV positive DLBCL 
ABC 
Ion mass(m/z) 
HIV negative DLBCL 
ABC 
Ion mass(m/z) 
2086.648 3025.453 1030.84 2042.259 
2042.731 3025.332 884.607 1837.372 
1837.687 686.579 860.685 860.115 
1837.651 665.747 859.642 649.315 
1837.444 649.617 729.781 649.29 
1065.886 649.496 665.759 649.266 
1059.936 643.716 643.679 649.242 
1059.9 643.692 627.683 648.903 
860.636 643.655 1030.84 643.316 
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854.759  884.607 2042.259 
854.662  860.685 1837.372 
854.529  854.323 860.115 
854.444  838.774 649.315 
838.944  729.781 649.29 
838.871  665.759 649.266 
665.905  664.705 649.242 
665.541  643.679 648.903 
 649.92  627.683 643.316 
649.533   
 
649.484   
 




8.5 Appendix E: List of differentially expressed proteins 
 





































































8.6 Appendix F: Exclusive protein ID’s for ABCN 
 
 
Figure 21 Numeric Venn Diagram ABC subtype 
8.7 Appendix G: Two-sample t-test Statistical analysis for GCBN and 
GCBP. 
Figure 22 
Two-sample t-test Statistical analysis for GCBN and GCBP. No protein was significantly 






Figure 23 Numeric Venn diagram showing exclusive proteins.  In GCBN and GCBP subtypes 
 
A Student t test HIV negative control (HVNC and ABCN) and (HVNC and GCBN) subtypes, 
and no protein was found to significantly different (Appendix G, figure.21 and 22). 
 
Figure 24 Two-sample t-test Statistical analysis for HVNC and ABCN. No protein was 








Figure 25. Two-sample t-test Statistical analysis for HVNC and ABCN. No protein was 



































8.8 Appendix I. A list of extranodal sites  
Table 9. A Breakdown of extranodal sites found in the HIV positive and HIV 
negative cases.  
HIV status  Subtype Site Specificity  
NEGATIVE ABC extranodal submandibular 
NEGATIVE ABC extranodal lymph node 
NEGATIVE ABC extranodal axilla 
NEGATIVE GCB extranodal mensenteric 
NEGATIVE GCB extranodal supraclavicular 
NEGATIVE GCB extranodal axillary 
POSITIVE  ABC extranodal testis 
POSITIVE ABC extranodal axillary 
POSITIVE ABC extranodal inguinal 
POSITIVE GCB extranodal mesenteric 
POSITIVE GCB extranodal right testis 
POSITIVE GCB extranodal axillary 
 
 
8.9 Appendix J. A list of potential protein biomarkers 
 
Table 10 : List of Potential Biomarkers 
Potential 
biomarker ID Proteins name 
Q99880 Histone 
D6RD66 Wdrepeat 
O75367-2 Isoform1 of Core histone macro 
B7Z7A9 Phosphoglycerate kinase 
P01024 Complement-C3 
P01834 Ig kappa chain-C region 
P01857 Ig gamma-4chain-C region 




P02792 Ferritin light chain 
P04075 Fructose-bisphosphate aldolase 









P07237 Protein disulfide-isomerase 
H0YMD0 Annexin(Fragment) 
F8VUJ7 Tubulinbetachain 









P11021 78kDa glucose-regulated protein 
P11142-2 Isoform2 of Heat shockcognate 71kDa protein 
P12109 Collagen alpha-1(VI)chain 
P12111-2 Collagen alpha-3(VI)chain 
P13639 Elongation factor2  
P13796 Plastin-2 
E7EVW7 Hematopoietic lineage cell-specific protein 
P14618 Pyruvate kinase isozymes M1/M2 
P16401 HistoneH1.5 
P16402 Histone H1.3 





P22626-2 IsoformA2 of Heterogeneous nuclearribonucleo proteinsA2/B1 
P23528 Cofilin-1 
P24821-5 Isoform 5 of Tenascin 







F5GZT4 Heterogeneous nuclear ribonucleo proteinH 
P35579 Myosin-9 
E9PDB2 Malatede hydrogenase,mitochondrial 
B4DYP2 Longchain3-hydroxyacyl-CoAdehydrogenase 
P42224-2 Isoform Beta of Signal transducer andactivator of transcription1-alpha/beta 
F5H571 Ubiquitincarboxyl-terminalhydrolase5(Fragment) 
P50395-2 Isoform2 of Rab GDP dissociation inhibitor beta 
P52272-2 Isoform2 of Heterogeneous nuclear ribonucleo proteinM 
P55072 Transitional endoplasmicreticulum ATPase 
F8WDD7 Actin-relatedprotein2 
P60174-1 Isoform2 of Triosephosphateisomerase 
P60709 Actin,cytoplasmic1 
P63267 Actin,gamma-entericsmoothmuscle 
A2A3R5 ribosomal proteinS6 
P62820-2 Isoform2 of Ras-related proteinRab-1A 
P62826 GTP-binding nuclear protein Ran 
P62937 Peptidyl-prolylcis-transisomeraseA 
B0AZS6 14-3-3proteinzeta/delta 
Q5VTE0 Putative elongation factor1-alpha-like3 
G3V1U9 Tubulinalpha-1A chain 
P68871 Hemoglobin sub unitbeta 
P69905 Hemoglobinsubunitalpha 
Q00839-2 IsoformShort of Heterogeneous nuclear ribonucleo proteinU 
Q01518 Adenylylcyclase-associated protein1 
H0YNE3 Proteasome activator complex subunit1 
Q07666-3 Isoform3 of KH domain-containing,RNA-binding,signal transduction-
associated protein1 
Q13263-2 Isoform2 of Transcription intermediary factor1-beta 
G8JLA8 Transforming growth factor-beta-induced protein ig-h3 
Q6S8J3 POTE ankyrin domain family member E 
Q86UX7-2 Isoform2 of Fermitin familyhomolog 3 
Q86VP6-2 Isoform2 of Cullin-associated NEDD8-dissociated protein1 
F8W914 Isoform5 of Reticulon- 
Q5TCU6 Talin1 
 
 
 
  
